MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5152/tjg.2020.19569

Медицинская библиотека · The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021

Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?

Demirtürk Neşe, Aygen Bilgehan, Çelik İlhami, Mıstık Reşit, Akhan Sıla, Barut Şener, Ural Onur, Batırel Ayşe, Şimşek Funda, Ersöz Gülden, İnan Dilara, Kınıklı Sami, Türker Nesrin, Bilgin Hüseyin, Gürbüz Yunus, Tülek Necla, Tarakçı Hüseyin, Yıldız Orhan, Türkoğlu Emine, Kamalak Güzel Deniz, Şimşek Sümeyra, Tuna Nazan, Aktuğ Demir Nazlım, Çağatay Atahan, Çetinkaya Rıza Aytaç, Karakeçili Faruk, Hakyemez İsmail Necati, Tuncer Ertem Günay, Örmen Bahar, Korkmaz Pınar, Yıldız Uluhan, Kuruüzüm Ziya, Şener Alper, Arslan Özel Selcan, Öztürk Sinan, Suer Kaya, Çelen Mustafa Kemal, Konya Petek, Asan Ali, Saltoğlu Neşe, Doğan Nurhan

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice.

METHODS

Data from patients with chronic hepatitis C treated with SOF/LDV ± RBV or SOF/RBV in 31 centers across Turkey between April 1, 2017, and August 31, 2018, were recorded in a nationwide database among infectious disease specialists. Demographics, clinical, and virological outcomes were analyzed.

RESULTS

A total of 552 patients were included in the study. The mean age of the patients was 51.28 ± 14.2, and 293 (55.8%) were female. The majority had HCV genotype 1b infection (65%), 75.04% of the patients underwent treatment, and non-cirrhosis was present at baseline in 381 patients (72.6%). SOF/LDV ± RBV treatment was given to 477 patients and 48 patients received SOF/RBV according to HCV genotype. The total SVR12 rate was 99% in all patients. Five patients experienced disease relapse during the study and all of them were genotype 2. In patients infected with HCV GT2, SVR12 was 77.3%. SVR was 100% in all patients infected with other HCV genotypes. All treatments were well tolerated by patients without causing severe adverse events. Side effects and side effects-associated treatment discontinuation rates were 28.2% and 0.4%, respectively. Weakness (13.7%) was the common side effect.

CONCLUSION

The present real-world data of 525 patients with HCV genotypes 1, 1a, 1b, 3, 4, and 5 who underwent SOF/LDV ± RBV treatment in Turkey demonstrated a high efficacy and safety profile. HCV GT2 patients should be treated with more efficacious treatment.

Для цитирования: Demirtürk Neşe, Aygen Bilgehan, Çelik İlhami, Mıstık Reşit, Akhan Sıla, Barut Şener, Ural Onur, Batırel Ayşe, Şimşek Funda, Ersöz Gülden, İnan Dilara, Kınıklı Sami, Türker Nesrin, Bilgin Hüseyin, Gürbüz Yunus, Tülek Necla, Tarakçı Hüseyin, Yıldız Orhan, Türkoğlu Emine, Kamalak Güzel Deniz, Şimşek Sümeyra, Tuna Nazan, Aktuğ Demir Nazlım, Çağatay Atahan, Çetinkaya Rıza Aytaç, Karakeçili Faruk, Hakyemez İsmail Necati, Tuncer Ertem Günay, Örmen Bahar, Korkmaz Pınar, Yıldız Uluhan, Kuruüzüm Ziya, Şener Alper, Arslan Özel Selcan, Öztürk Sinan, Suer Kaya, Çelen Mustafa Kemal, Konya Petek, Asan Ali, Saltoğlu Neşe, Doğan Nurhan. Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. 2021. DOI: 10.5152/tjg.2020.19569.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.